Detail akcie Anika Therapeut online

Business Summary: Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Anika Therapeutics Inc revenues increased 7% to $166.7M. Net loss increased from $14.9M to $82.7M. Revenues reflect Orthopedic Joint Preservation and Restoration segment increase of 9% to $54.9M, Joint Pain Management segment increase of 4% to $101.9M, Other segment increase of 33% to $21.8M, United States segment increase of 3% to $123.1M.